109 results
S-3ASR
AKRO
Akero Therapeutics Inc
10 May 24
Automatic shelf registration
4:57pm
Outcomes. SYNCHRONY Histology is evaluating the safety and efficacy of 28 and 50mg doses of EFX in patients with biopsy confirmed pre-cirrhotic MASH … is assessing the safety and tolerability of EFX in patients with non-invasively diagnosed MASH or MASLD with an estimated enrollment of 700 patients
8-K
EX-99.1
AKRO
Akero Therapeutics Inc
10 May 24
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
7:17am
, a Phase 2b study evaluating the efficacy and safety of efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated … SYMMETRY Study
The ongoing Phase 2b SYMMETRY study, which is evaluating the efficacy and safety of EFX in patients with compensated cirrhosis due
8-K
EX-1.1
AKRO
Akero Therapeutics Inc
6 Mar 24
Entry into a Material Definitive Agreement
5:25pm
enforceable requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances
424B5
AKRO
Akero Therapeutics Inc
6 Mar 24
Prospectus supplement for primary offering
5:16pm
cohort in patients with pre-cirrhotic MASH (F1-F3) and type 2 diabetes, known as Cohort D, which evaluated the safety and tolerability of EFX compared … Outcomes. SYNCHRONY Histology is evaluating the safety and efficacy of 28 and 50mg doses of EFX in patients with biopsy confirmed pre-cirrhotic MASH
424B5
susgbui3e4qi8e
4 Mar 24
Prospectus supplement for primary offering
5:21pm
8-K
ynjl1
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
8-K
EX-99.2
v04a2
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
8-K
EX-99.1
162g359r2 92rcd
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
8-K
EX-99.1
wnikma5x alsqgj
29 Feb 24
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:15am
8-K
13a nfqmn5ix545
18 Dec 23
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
7:08am
8-K
EX-99.1
rxat ykx7y
18 Dec 23
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
7:08am
8-K
EX-99.1
7199kv59v b5lxfu
13 Nov 23
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:15am
8-K
s7n4ll n4p9733q0
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.2
9vw7uho
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.1
2h84l8fhxq 8sm0z
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.1
62chwblhl6jxrs3ejzc
11 Aug 23
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
6:09am